Actelion
Beyond Batten Disease Foundation partners with Actelion on development of combination treatment
March 4, 2021Actelion, Batten disease, Janssen
Beyond Batten Disease Foundation (BBDF) has partnered with Actelion Pharmaceuticals, a Janssen company, to provide Zavesca (miglustat) for the development of …
Pharmafile.com’s top ten stories of 2017
December 22, 2017Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing Abbott, Actelion, Amgen, AstraZeneca, Cyber attack, EMA, European Commission, Humira, J&J, JJ, Johnson & Johnson, MSD, Sanofi, Shire, Teva, biosimilar, brexit
After a packed year that has flown by, we’ve reached the final top ten of 2017. Below you can find …
Actelion spin-off hit by blow shortly before buyout
June 9, 2017Medical Communications, Research and Development Actelion, Idorsia, J&J, JJ
Idorsia, the spin-off R&D company of Actelion, has been hit a blow even before it has left the ground. The …
J&J lines up its Global Head for Actelion
May 22, 2017Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing Actelion, Janssen, Johnson & Johnson
The deal is not yet complete but the last steps are assumed to be a formality – at least Johnson …
Janssen acquires over 90% of Actelion
April 24, 2017Sales and Marketing Actelion, Janssen
Actelion has revealed that, following the wrap of its $30 billion deal in January, Janssen Holding has acquired 92.51% of …
EMA green lights Actelion’s drug after patient deaths scare
April 10, 2017Sales and Marketing Actelion, Johnson & Johnson, Uptravi
The EMA has ruled that the five patient deaths that occurred in February of this year were not directly related …
The March 2017 issue of Pharmafocus is now live!
February 22, 2017Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing Actelion, FDA, Johnson & Johnson, MSD, Roche, Trump, crispr, immunotherapy, opdivo
The latest edition of Pharmafocus is available to read online now! From breakthroughs in antibiotic resistance R&D to gene editing …
J&J finally seals $30 billion deal for Actelion
January 26, 2017Sales and Marketing Actelion, Janssen, Johnson & Johnson
Johnson & Johnson has, as expected, wrapped up the deal to acquire Actelion in a deal worth $30 billion, working …
Actelion acquisition hokey-cokey continues with J&J returning to table
December 22, 2016Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing Actelion, Johnson & Johnson, Sanofi
The Actelion takeover saga continues with Johnson & Johnson back in the game, and now re-entering into exclusive negotiations. Actelion …
Sanofi eyes Actelion merger as J&J backs down
December 14, 2016Medical Communications, Research and Development, Sales and Marketing Actelion, Johnson & Johnson, Sanofi
After days of negotiations, Johnson and Johnson has stepped down from its attempts to acquire Swiss blood-pressure specialist Actelion, while …
J&J reportedly poised to acquire Europe’s biggest biotech
November 25, 2016Sales and Marketing Actelion, J&J, JJ, Johnson and Johnson, acquisition
Johnson & Johnson could be eyeing a takeover of Swiss biotech Actelion, Europe’s biggest biotech, according to insiders, Bloomberg has …
Actelion says blood pressure drug Uptravi now available in Germany
June 15, 2016Research and Development, Sales and Marketing Actelion, EU, blood pressure, product launch
Actelion (SIX: ATLN) said its high blood pressure drug Uptravi (selexipag) is now available in Germany. The European Commission granted …
Actelion granted EU approval for hypertension treatment
May 17, 2016Manufacturing and Production, Sales and Marketing Actelion, Uptravi, eu approval, hypertension
Actelion Pharmaceuticals has received marketing authorisation from the European Commission for Uptravi (selexipag) for the long-term treatment of patients with …
Actelion ups outlook for 2016, reports Q1 net income up 12%
April 22, 2016Medical Communications, Sales and Marketing Actelion, Biotechnology, Q1 results, earnings, outlook
Swiss biotech company Actelion (VTX: ATLN) raised its outlook for 2016 and reported a 12% rise in first quarter net …
Actelion’s Uptravi goes on sale
January 5, 2016Manufacturing and Production, Sales and Marketing Actelion, PAH, Uptravi, pulmonary arterial hypertension, pulmonary hypertension, selexipag
Swiss pharma firm Actelion has put its new drug for pulmonary hypertension, Uptravi, up for sale in the US, weeks …
